illuminem logo
illuminem logo
  • Rankings
  • Use Cases
  • Pricing
  • Media
  • More
illuminem logo

About illuminem

AboutCareersBecome a Thought Leader

Advertising

Advertise with usPromote EventsOur Reach

Support

FAQsContact Us
Terms & Privacy Policy

© 2026 illuminem. All rights reserved. Various trademarks held by their owners.

  1. Home
  2. ›
  3. Industries
  4. ›
  5. health care
  6. ›
  7. Santen Pharmaceutical
Company logo

Santen Pharmaceutical | Sustainability Performance

https://www.santen.com/

Pharmaceutical company specializing in ophthalmic products and treatments.

1890

Japan

1,001 - 5,000 employees

Pharmaceuticals

$1B - 10B in revenue

Submit or report inaccurate dataDownload Company Insights

Sustainability Ranking & Industry Benchmark

#2665
Overall
#143
in Japan
#64
in Pharmaceuticals

Sustainability Maturity

​​0123456789​​%

Sustainability Intent

Available in
Scale package

Access
​​0123456789​​%

Industry Rank

95 out of 292

Overview
Governance
TargetsESG scores and Exclusions
Financial Data
Business performanceCapital & innovationAnalyst projections

View similiar companies

Company logo
Rici Healthcare

Japan, Health Care, Hospital & Health Care

Company logo
Takeda Pharmaceutical

Japan, Health Care, Pharmaceuticals

Company logo
Sumitomo Pharma

Japan, Health Care, Pharmaceuticals

Market cap

648.7B $, 2026▼13% YoY

Revenue

300.0B $, 2025▲0.7% YoY

R&D intensity

8.03% 2025

Controversy level

Very Low
Low
Noticeable
High
Severe
Download Controversy Analysis
  • Santen Pharmaceutical Co Ltd, Japanese ophthalmology major, has faced multiple US FDA Form 483 observations at multiple production facilities following the contested 2024 sustained share price volatility amid Asian ophthalmology customer demand normalization, plus periodic Japanese FSA enforcement scrutiny on inadequate disclosure of glaucoma drug customer concentration affecting Japanese institutional shareholders.
Powered by illuminem

Market cap

648.7B $, 2026▼13% YoY

Revenue

300.0B $, FY2025▲0.7% YoY

EBITDA

57.3B $, FY2025▼9.1% YoY

Operating margin

16% Industry: -33▲7.9% YoY

P/E ratio

15.7 Industry: 26▲42.6% YoY

Revenue & EBITDA

$300.0BFY2025 revenue

Total Annual
Revenue & EBITDA
($ B)

Annual revenue
EBITDA
3 year change
Powered by illuminem

Margin trends

Margin as % of revenue

Gross margin
Operating margin
Net margin

Powered by illuminem

Free cashflow

49.9B 2025▲24.1% YoY

Capex

11.0B 2025▼3% YoY

Debt/equity ratio

0.1 Industry: 0▼NaN% YoY

R&D intensity

8.0%FY2025

R&D as % of revenue

Return on invested capital (ROIC)
Industry benchmark

Powered by illuminem

Return on invested capital

11.0%FY2026
Return on invested capital (ROIC)
Industry benchmark

Powered by illuminem

Analyst revenue estimates & actuals

Analyst consensus vs actuals
($ B)

Actual revenue
Consensus estimates
Estimate only

279.0

▲ 1.3%

2023

302.0

▼ 1.5%

2024

300.0

▼ 0.4%

2025

310.8

2028

Powered by illuminem

Environmental policy coverage

Carbon reduction policy

Available

Human rights policy

Available

Recycling policy

Available

Workplace health & safety policy

Available

16%
Independent Directors

4 out of 25 incl. management

Powered by illuminem

Overall score

88

Environment

99

Social

99

Governance

66

Exclusion screening

Adult content

Not available

Alcoholic

Not available

Animal testing

Available

Firearms

Not available

Tobacco

Not available

Gambling

Not available

Nuclear

Not available

Powered by illuminem

Reporting

sustainability report symbol

Sustainability Report

 Available
image report
Available
image report
Available

Sustainability employees

Total sustainability employees

7-10

    Available in
    Scale package

    Access
  • Email
  • Email